MedTrace Logo

Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University

NCT04885764 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 4000

Last updated 2021-05-13

No results posted yet for this study

Summary

This is a prospective intervention study to assess the effectiveness of both the live attenuated and messenger RNA vaccines against SARS-CoV-2 infection

Conditions

  • Covid19

Interventions

BIOLOGICAL

Astrazeneca/Oxford Vaccine

Viral non replicated vector vaccine contains the gene that encodes for the spike protein on the surface of the SARS-CoV-2 virus given Intramuscular injection in 2 doses 3 months apart

BIOLOGICAL

Sinopharm vaccine

Inactivated vaccine given intramuscular injection in 2 doses 3 weeks apart

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Samia E Girgis, M.D · Faculty of Medicine Ain Shams University

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-23
Primary Completion
2021-10-01
Completion
2021-12-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04885764 on ClinicalTrials.gov